{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-011585","form_type":"8-K","ticker":"GANX","cik":"0001819411","company_name":"Gain Therapeutics, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.654812+00:00","generated_at":"2026-05-31T11:10:08.828641+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Gain Therapeutics Q2 net loss $0.42/shr; expects MAD Phase 1 topline for GT-02287 in August 2024","bullets":["Net loss per share $0.42 for Q2 2024 vs $0.62 in Q2 2023; cash & securities $16.9M as of June 30, 2024.","Topline results from MAD Phase 1 study of GT-02287 for Parkinson's disease expected in August 2024.","Phase 1b study in Parkinson's patients with/without GBA1 mutation initiation anticipated in Q4 2024.","Gene Mack appointed interim CEO and CFO; Khalid Islam serves as Executive Chairman.","Completed underwritten public offering with approximately $10.0M net proceeds."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-011585","json":"https://secwatch.observer/filing/0001558370-24-011585.json","markdown":"https://secwatch.observer/filing/0001558370-24-011585.md","text":"https://secwatch.observer/filing/0001558370-24-011585.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819411/000155837024011585/0001558370-24-011585-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819411/000155837024011585/ganx-20240808x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:10:08.828641+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}